Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


March 28, 2015 3:39 PM ET

Biotechnology

Company Overview of Aridis Pharmaceuticals Inc.

Company Overview

Aridis Pharmaceuticals Inc., a biopharmaceutical company, develops anti-infective product candidates. The company offers AR-301, an anti-Staphylococcus aureus human monoclonal antibody to treat acute pneumonia; AR-101 and AR-104 that are specific lgM monoclonal antibodies, which target pseudomonas aeruginosa; and Aerucin, a broadly reactive monoclonal antibody against Pseudomonas aeruginosa. It also provides Panaecin, a small molecule anti-infective gallium compound with broad spectrum activities against bacteria, viruses, and fungi; AR201, a human monoclonal antibody, which treats respiratory syncytial virus infections; and AR401, a human monoclonal antibody for the treatment of Nosocomial ...

5941 Optical Court

San Jose, CA 95138

United States

Founded in 2003

Phone:

408-385-1742

Fax:

408-960-3822

Key Executives for Aridis Pharmaceuticals Inc.

Co-Founder, Chief Executive Officer and Director
Co-Founder, Chairman and President
Head of Finance
Chief Medical Officer
Acting General Counsel
Age: 59
Compensation as of Fiscal Year 2014.

Aridis Pharmaceuticals Inc. Key Developments

Aridis Pharmaceuticals Commences Phase 1 Clinical Study of Aerucin™ Monoclonal Antibody for Acute Pneumonia

Aridis Pharmaceuticals Inc. announced the initiation of a Phase 1 clinical study of Aerucin™, the Company's fully human IgG1 monoclonal antibody (mAb) against Pseudomonas aeruginosa bacteria, which is being developed as an adjunctive treatment for acute pneumonia. Aerucin has also filed for Orphan Disease Designation with the U.S. Food and Drug Administration in the United States and in Europe. The clinical trial, expected to complete in the third quarter of 2015, is a Phase 1 single ascending dose study in healthy volunteers. Advancing to this stage of development represents the culmination of longstanding collaborations with Harvard University and the National Institutes of Health. Aerucin directly binds the alginate polysaccharide on the cell surface of P. aeruginosa. It was discovered using Aridis' proprietary MabIgX® technology by screening human B-cells for antibodies that demonstrated improved immune recognition and phagocytic destruction of more than 90% of all Pseudomonas aeruginosa. Earlier preclinical studies of Aerucin support both therapeutic and prophylactic use of the monoclonal antibody.

Aridis Pharmaceuticals Inc. Appoints Paul-Andre de Lame as Chief Medical Officer

Aridis Pharmaceuticals Inc. announced the appointment of Paul-Andre de Lame, M.D., as the company's Chief Medical Officer. Dr. de Lame founded Anabase International Corp. and was a co-founder and Chief Medical Officer of Cardiokine Inc.

Aridis Pharmaceuticals Inc. Presents at BioCentury 22nd Annual Future Leaders in the Biotech Industry Conference, Mar-20-2015 03:20 PM

Aridis Pharmaceuticals Inc. Presents at BioCentury 22nd Annual Future Leaders in the Biotech Industry Conference, Mar-20-2015 03:20 PM. Venue: Millennium Broadway Hotel & Conference Center, New York, New York, United States.

Similar Private Companies By Industry

Company Name Region
Dilyx Biotechnologies, LLC United States
Medicinal Genomics Corporation United States
Dynamis Therapeutics, Inc. United States
Differential Proteomics, Inc. United States
Boston Biomedical Research Institute, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
September 18, 2014
--
Private Placement
May 31, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Aridis Pharmaceuticals Inc., please visit www.aridispharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.